单激素受体阳性与双激素受体阳性乳腺癌的结局:GEICAM/9906亚研究
该研究基于GEICAM/9906试验,对571例HER2阴性、ER和/或PgR阳性早期乳腺癌患者进行PAM50内在亚型分析,比较单激素受体阳性(sHR+)与双激素受体阳性(dHR+)的临床结局。结果显示ER+/PgR-患者DFS和OS均显著差于ER+/PgR+患者,而ER-/PgR+患者结局与ER+/PgR+相似但样本量小。
要点
- ER+/PgR-患者DFS显著差于ER+/PgR+(HR 1.60, 95%CI 1.12-2.28, p<0.01)。
- ER+/PgR-患者OS也显著差于ER+/PgR+(HR 1.86, p<0.01)。
- ER-/PgR+患者DFS和OS与ER+/PgR+相似,但样本量小无法得出结论。
核心结论
- ER+/PgR-组增殖更高且结局更差。
- ER-/PgR+亚组在分子亚型和结局上与ER+/PgR+相似,但患者数少无法得出结论。
研究设计与样本
- 回顾性分析GEICAM/9906研究(NCT00129922)中HER2阴性乳腺癌患者。
- 对571例(50%)ER+和/或PgR+患者的存档肿瘤进行ER、PgR、HER2检测及PAM50内在亚型分类。
- 采用Cox比例风险模型分析无病生存(DFS)和总生存(OS)。
主要发现
- dHR+(ER+/PgR+)肿瘤中luminal A和B亚型发生率分别为52%和36%。
- ER+/PgR-肿瘤中luminal A和B亚型发生率分别为15%和58%。
- ER-/PgR+肿瘤主要为luminal A(52%)。
- 与ER+/PgR+相比,ER-/PgR+的DFS相似(HR 1.15, 95%CI 0.57-2.34, p=0.70),ER+/PgR-的DFS更差(HR 1.60, 95%CI 1.12-2.28, p<0.01)。
- OS结果相似:ER-/PgR+ HR 1.50(p=0.30),ER+/PgR- HR 1.86(p<0.01)。
临床怎么用
- ER+/PgR-早期乳腺癌患者可能具有更高增殖和更差预后,需更密切随访。
- ER-/PgR+患者分子亚型和结局与ER+/PgR+相似,但证据有限。
局限性
- 回顾性分析,仅50%患者有内在亚型数据。
- ER-/PgR+亚组患者数少,无法得出可靠结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Retrospective data suggest better outcomes for patients with double hormonal receptor (oestrogen [ER] and progesterone receptor [PgR])-positive (dHR+) early breast cancer, compared with single hormonal receptor-positive, sHR+, (ER+/PgR- or ER-/PgR+) disease. Here, we evaluate the classification according to intrinsic subtypes and clinical outcomes of sHR+ versus dHR+ in HER2-negative breast cancer patients enrolled in GEICAM/9906 study (NCT00129922). METHODS: Archival tumours were retrieved retrospectively for the analysis of ER, PgR and HER2 status and classified into intrinsic subtypes using the PAM50 gene expression assay. Disease-free survival (DFS) and overall survival (OS) were explored using a Cox proportional hazard analysis. RESULTS: Data on intrinsic subtypes were available in 571 (50%) patients with ER+ and/or PR+, and HER2-negative primary tumours. The incidence of luminal A and luminal B subtypes were 52%/36% in dHR+ tumours (ER+/PgR+), and 15%/58% in ER+/PgR-tumours. ER-/PgR+ tumours were mainly luminal A (52%). Compared with ER+/PgR+ patients, DFS was similar in ER-/PgR+ (hazard ratio [HR] 1.15, 95% confidence interval [CI] 0.57-2.34, p = 0.70) but worse in ER+/PgR- patients (HR 1.60, 95% CI 1.12-2.28, p < 0.01). Similar results were observed for OS (HR 1.50, p = 0.30 and HR 1.86, p < 0.01, respectively). CONCLUSIONS: The ER+/PgR- group is characterised by higher proliferation and worse outcomes. In spite of the ER-/PgR+ subgroup resembles ER+/PgR+ disease in terms of molecular subtypes and outcomes, the small number of patients in this subgroup prevents from drawing any conclusions. TRIAL REGISTRATION: EudraCT: 2005-003108-12 (retrospectively registered 28/06/2005). CLINICALTRIALS. GOV IDENTIFIER: NCT00129922 (retrospectively registered 10/08/2005).
引用
- Ethier JL, Ocaña A, Rodríguez Lescure A, et al. Outcomes of single versus double hormone receptor-positive breast cancer. A GEICAM/9906 sub-study. Eur J Cancer. 2018. PMID: 29573665. doi:10.1016/j.ejca.2018.02.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。